Novartis (NVS) announced new data from the Phase III PSMAddition trial demonstrating improved prostate-specific antigen (PSA) responses with Pluvicto combined with standard of care (SoC) in PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC). Data were presented as a rapid oral presentation...
Outlook Therapeutics, Inc. (OTLK), a biopharmaceutical company, announced financial results for the second quarter of fiscal year 2026, ended March 31, 2026, and provided a corporate update. Company Profile Outlook Therapeutics is developing and commercialising ONS-5010/LYTENAVA (bevacizumab-vikg),...